Suchergebnisse - Ho Yeong Lim
- Treffer 1 - 20 von 80
- Zur nächsten Seite
-
1
Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma von Youngil Koh, Ho Yeong Lim, J.-H. Ahn, J. L. Lee, Sun Young Rha, Yoon Jun Kim, T. M. Kim, Seung‐Hoon Lee
Veröffentlicht 2012Artigo -
2
-
3
Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review von Joon Oh Park, Do‐Youn Oh, Chiun Hsu, Jen‐Shi Chen, Li‐Tzong Chen, Mauro Orlando, Jong Seok Kim, Ho Yeong Lim
Veröffentlicht 2015Revisão -
4
-
5
c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival von Su Jin Lee, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Young Suk Park, Seung Tae Kim
Veröffentlicht 2018Artigo -
6
-
7
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study von Jordi Bruix, Won Young Tak, Antonio Gasbarrini, Armando Santoro, M. Colombo, Ho-Yeong Lim, Vincenzo Mazzaferro, Reiner Wiest, María Reig, Thierry André, Luigi Bolondi
Veröffentlicht 2013Artigo -
8
P21-Activated Kinase 4 Overexpression in Metastatic Gastric Cancer Patients von Hee Kyung Ahn, Jiryeon Jang, Jeeyun Lee, Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Kyoung‐Mee Kim, Won Ki Kang
Veröffentlicht 2011Artigo -
9
-
10
-
11
Impact of epidermal growth factor receptor (EGFR) kinase mutations, <i>EGFR</i> gene amplifications, and <i>KRAS</i> mutations on survival of pancreatic adenocarcinoma von Jeeyun Lee, Kee‐Taek Jang, Chang‐Seok Ki, Taekyu Lim, Young Suk Park, Ho Yeong Lim, Dongwook Choi, Won Ki Kang, Keunchil Park, Joon Oh Park
Veröffentlicht 2007Artigo -
12
Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy von Seung Tae Kim, Samuel J. Klempner, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Kyoung-Mee Kim, Jeeyun Lee
Veröffentlicht 2017Artigo -
13
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma von Changhoon Yoo, Joong‐Won Park, Yoon Jun Kim, Do Young Kim, Su Jong Yu, Tae Seop Lim, Su Jin Lee, Baek‐Yeol Ryoo, Ho Yeong Lim
Veröffentlicht 2018Artigo -
14
Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma von Chan Kim, Hannah Yang, Il Hwan Kim, Beodeul Kang, Hyeyeong Kim, Hyunho Kim, Won Suk Lee, Sanghoon Jung, Ho Yeong Lim, Jaekyung Cheon, Hong Jae Chon
Veröffentlicht 2022Artigo -
15
Whole-genome sequencing of matched primary and metastatic hepatocellular carcinomas von Limei Ouyang, Jeeyun Lee, Cheol-Keun Park, Mao Mao, Yujian Shi, Zhuolin Gong, Hancheng Zheng, Yingrui Li, Yonggang Zhao, Guangbiao Wang, Huiling Fu, Jhingook Kim, Ho Yeong Lim
Veröffentlicht 2014Artigo -
16
Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcino... von Shukui Qin, Yuxian Bai, Ho Yeong Lim, Sumitra Thongprasert, Yee Chao, Jia Fan, Tsai‐Shen Yang, Vajarabhongsa Bhudhisawasdi, Won Ki Kang, Yu Zhou, Jee Hyun Lee, Yan Sun
Veröffentlicht 2013Artigo -
17
Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma von Thomas E. Hutson, Bernard Escudier, Emilio Esteban, Georg A. Bjarnason, Ho Yeong Lim, K. Pittman, P. Senico, Andreas G. Niethammer, Dongrui R. Lu, Hariharan Subramanian, Robert J. Motzer
Veröffentlicht 2013Artigo -
18
Temsirolimus vs Sorafenib As Second Line Therapy in Metastatic Renal Cell Carcinoma: Results from the Intorsect Trial von Thomas E. Hutson, Bernard Escudier, E. Barrado, Georg A. Bjarnason, Ho Yeong Lim, K. Pittman, P. Senico, Andreas G. Niethammer, Dongrui R. Lu, Seetharaman Hariharan, Robert J. Motzer
Veröffentlicht 2012Artigo -
19
-
20
Suchwerkzeuge:
Ähnliche Schlagworte
Medicine
Internal medicine
Oncology
Cancer
Gastroenterology
Hepatocellular carcinoma
Sorafenib
Surgery
Chemotherapy
Clinical endpoint
Biology
Colorectal cancer
Adverse effect
Immunotherapy
Pathology
Randomized controlled trial
Confidence interval
Cancer research
Alternative medicine
Biochemistry
Nivolumab
Placebo
Gene
Hazard ratio
Phases of clinical research
Sunitinib
Renal cell carcinoma
Urology
Clinical trial
Bevacizumab